<DOC>
	<DOCNO>NCT01970280</DOCNO>
	<brief_summary>The aim study evaluate effect Enoxaparin ( LMWH ) incidence AV graft thrombose patient chronic hemodialysis . Primary efficacy end point study : compare time onset new thrombotic event successful angiography AV graft . Pprimary safety outcome study : frequency hemorrhage . Design method : Following first AV graft thrombosis successful thrombolysis angioplasty , patient chronic hemodialysis randomize s.c Enoxaparin ( Clexane ) 0.5 mg/1kg body weight per day control group ( Clexane ) . Patients follow year till next AV graft thrombotic occlusion , occur . In group compare time period month first recurrent thrombotic event AVG evaluation difference two sample mean . Also interim analysis AV graft patency two group evaluate different time point : three , six twelve month randomization . Patients group receive unfractionated heparin dialysis session prevent thrombosis extracorporeal circulation . Patients Enoxaparin group receive half dose ( 500 units/hour ) prevent possible risk bleeding session . Before randomization patient evaluate hypercoagulability state include : Factor V Laden deficiency , Anti phospholipid antibody ( APLA ) , Antithrombin III deficiency Protein C/S deficiency .</brief_summary>
	<brief_title>Low Molecular Weight Heparin Prevention Recurrent Arteriovenous Graft Thrombosis Chronic Hemodialysis Patients .</brief_title>
	<detailed_description />
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<criteria>hemodialysis patient ≥ 18 year age occurrence AVG thrombosis successful thrombolysis/thrombectomy angioplasty . 1 . Known allergy enoxaparin 2 . Persistent systolic blood pressure 180 and/or persistent diastolic blood pressure 100 3 . Chronic Warfarin treatment 4 . Double antiagregant treatment ( aspirin plus clopidogrel ) 5 . Platelets count 80000/µl 6 . Known HIT ( Heparin Induced Thrombocytopenia ) 7 . Recent bleeding ( &lt; 2 week ) 8 . Recent stroke ( &lt; 4 week ) 9 . Reduced mental status inability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>